Full-Time

Director of AI Engineering

Vaccine R&D Operations Enablement

Posted on 6/20/2026

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$176.6k - $294.3k/yr

+ 20% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Pearl River, NY, USA

Hybrid

Hybrid role requiring an average of 2.5 days on-site per week and residence within commuting distance.

Master's, PhD

Category
AI & Machine Learning (1)
Required Skills
MLOps
Python
High Performance Computing (HPC)
TensorFlow
PyTorch
Machine Learning

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A PhD in Computer Science, Machine Learning, Data Science, Software Engineering, Artificial Intelligence, or a related discipline and at least 5 years of applied analytical experience with demonstrated impact in operations, automation, business analytics, or decision support, or a Master's degree in those fields and at least 7 years of such experience.
  • At least 2 years of artificial intelligence or machine learning experience in a relevant domain.
  • Strong understanding of process-heavy environments, ideally within research and development, clinical operations, or large-scale regulated organizations.
  • Expertise in predictive modeling, optimization, automation, generative artificial intelligence, and machine learning system design.
  • Strong programming skills in Python and modern machine learning frameworks such as PyTorch and TensorFlow, plus experience scaling models in cloud or high-performance computing environments.
  • Experience collaborating across scientific, operational, quality, and business teams and translating complex needs into practical artificial intelligence solutions.
  • Clear communication skills.
  • Candidates must be authorized to be employed in the United States by any employer.
  • Permanent work authorization in the United States is required.
Responsibilities
  • Define and deliver artificial intelligence solutions for process-heavy laboratory and office workflows, including experiment tracking, documentation, handoffs, and operational reporting.
  • Drive automation of manual and repetitive activities across vaccine development to improve speed, quality, consistency, and compliance.
  • Develop predictive, optimization, and scenario-based models for resource planning, capacity management, timeline forecasting, and risk trade-offs.
  • Develop dashboards and decision-support tools that translate complex operational data into actionable insights for research and development and leadership teams.
  • Design artificial intelligence solutions aligned with GxP expectations, data integrity standards, and inspection readiness, supporting deviation monitoring, CAPA trending, documentation completeness, data genealogy, and audit preparedness.
  • Establish governance models covering model validation, versioning, explainability, monitoring, and lifecycle management in regulated environments.
  • Build artificial-intelligence-enabled capabilities for development planning, milestone tracking, dependency management, and execution risk forecasting across the vaccine development lifecycle.
  • Lead process optimization and reengineering initiatives using artificial intelligence, automation, and data-driven methods to simplify workflows and reduce cycle times.
  • Architect and deploy robust, production-ready machine learning and analytics pipelines with governance, reproducibility, and monitoring.
  • Scale artificial intelligence solutions in cloud and high-performance computing environments, ensuring reliability, security, and integration with existing research and development, financial, and operational systems.
  • Act as a strategic bridge between technical teams and scientific, operational, quality, and business stakeholders to ensure adoption and measurable value.
  • Mentor engineers and operational partners and raise artificial intelligence and data literacy across vaccine research and development.
  • Champion best practices in MLOps, software engineering, and artificial intelligence system lifecycle management.
Desired Qualifications
  • Experience in life sciences, pharmaceuticals, research and development, clinical operations, or other regulated industries.
  • Financial and business experience supporting budgets, forecasting, vendor management, or portfolio analytics.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 4 August 2026 guidance rose to $60.5 billion-$62.5 billion on non-COVID growth.
  • Eliquis delivered $2.43 billion in Q2 2026, up 19%, offsetting COVID declines.
  • Additional $2.5 billion savings from 2027-2029 supports margins and cash returns.

What critics are saying

  • Eliquis faces patent pressure by 2028, threatening Pfizer's largest current revenue engine.
  • Pfizer cut Catania 370 jobs on 7 July 2026, signaling restructuring pain.
  • COVID sales keep shrinking; low Paxlovid demand and Comirnaty seasonality expose a weak base.

What makes Pfizer unique

  • Pfizer's 2026 scale spans Eliquis, Padcev, Prevnar 20, and Comirnaty globally.
  • July 2026 Padcev-Keytruda approval deepens Pfizer's oncology franchise beyond COVID dependence.
  • Pfizer's manufacturing and distribution reach lets Québec, hospitals, and governments adopt products quickly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.

Yahoo Finance
Aug 4th, 2026
Pfizer Q2 earnings beat at 77¢/share, revenue guidance raised to $62.5B on non-COVID growth

Pfizer reported second-quarter revenue of $15.03 billion and raised its full-year revenue guidance to $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion. Adjusted earnings reached 77 cents per share, beating the 68-cent consensus estimate. Revenue growth was led by Eliquis, which rose 19% operationally, and Padcev, which climbed 23%. Paxlovid fell 95% amid lower COVID-19 infection rates, whilst Comirnaty declined 34%. Excluding COVID products, revenues grew 5% operationally. The company announced an additional $2.5 billion in cost savings expected from 2027 through 2029. CFO Dave Denton is departing on 15 August, with Cecile Guegan stepping in as interim CFO. Pfizer shares rose 1.8% to $25.50 in premarket trading.

Yahoo Finance
Aug 3rd, 2026
Pfizer returned $49B to shareholders but stock fell 21% over five years

Pfizer returned $49 billion to shareholders over five years through dividends and buybacks, equal to 34% of its current market value. Despite this substantial cash distribution, the stock delivered a -21% total return whilst the S&P 500 gained 81% over the same period. The pharmaceutical giant generated the payouts from a $63 billion business with a 25% operating margin. Of the total returned, $47 billion came from dividends and $2 billion from share repurchases. Management has affirmed its commitment to maintaining and growing dividends whilst reducing leverage. However, the company faces a "patent cliff" with $14-15 billion in annual revenue at risk from loss of exclusivity. Revenue growth stands at just 1.4% over the last twelve months, raising concerns that heavy payouts reflect fewer high-return reinvestment opportunities as core growth engines slow.

INACTIVE